Cardiology Perspective

 
 
  • Best & Worst Places to Practice 2021 Medscape ranked states and cities on the basis of livability, financial, and malpractice factors to offer places that create an enjoyable practice environment.
  • May 21 2021 This Week in Cardiology   John Mandrola, MD, presents an ACC 2021 recap.
  • ACC 2021 Renal Denervation for Resistant Hypertension Is Not Back on Track The RADIANCE-HTN-TRIO presentation at the recent American College of Cardiology meeting has this cardiologist asking if mineralocorticoid inhibition might beat an invasive procedure for resistant hypertension.
  • ACC 2021 Acute Alcohol Consumption Raises Risk for Atrial Fibrillation   Dr Gregory Marcus discusses his study results showing that the risk for AF is increased in the few hours after even moderate alcohol intake.
  • EuroPCR 2021 Read clinically focused news coverage of key developments from EuroPCR 2021
  • ACC 2021 Sacubitril/Valsartan: Trending Toward PARADISE Post MI?   PARADISE-MI fell short on statistical significance but investigator Marc Pfeffer is persuaded by trends for clinical benefit. The key: 'Start the drug early and sustain it,' he tells Ileana Pina.
  • The Mediterranean Diet Gets a Green Boost Modifying the Mediterranean diet with additional green plant-based proteins/polyphenols results in intriguing benefits.
  • Palliative Care Update for Clinicians Timely initiation of palliative care services is a challenge, especially for those with noncancer diagnoses, but recent studies offer novel approaches to end-of-life care planning across settings.
  • ACC 2021 Does ADAPTABLE Inform Aspirin Dosing for Secondary Prevention?   Patient engagement, social media, and the internet all contributed to the unique design of the ADAPTABLE trial, but did it answer the question on the best dose of aspirin to use?
  • ACC 2021 PARADISE-MI Makes Me Question the Benefits of Sacubitril/Valsartan Sacubitril valsartan (Entresto), deemed 'the Big E' by some clinicians, has fallen short in 2 of 3 clinical trials. The latest, presented at the ACC 2021 scientific session, is PARADISE-MI.
  • ACC 2021 Eight Things to Know About the LAAOS III Trial The trial, showing a benefit for surgical left appendage occlusion in patients with AF undergoing cardiac surgery, should change practice, but there are caveats, notes John Mandrola, MD.
  • Imagine the Worst, or We're at Our Own Peril: Osterholm   At home with politicians and news anchors, CIDRAP's Michael Osterholm shares three rules of science and the media, and explains why policy and science belong together like chocolate and peanut butter.
  • ACC 2021 Read clinically focused news coverage of key developments from ACC 2021
  • Medscape Cardiologist Compensation Report 2021 Medscape's Cardiologist Compensation Report 2021 explores income, hours worked, and greatest work challenges in 2020, an atypical year marked by the COVID pandemic.
  • Q&A With Dr. John Whyte (May 14, 2021)   WebMD's Chief Medical Officer, John Whyte, MD, MPH, answers viewers' questions about COVID-19 vaccines and blood thinners, infectiousness, and gatherings.
  • May 14 2021 This Week in Cardiology   The upcoming ACC meeting, polypharmacy, finerenone, and ethics and professionalism are the topics covered by John Mandrola, MD, in this week’s podcast.
  • Disparities in SGLT2i Use: Patient Barriers or Physician Bias? A recent study suggests that although the use of SGLT2 inhibitors has increased overall, certain groups are not being prescribed these medications. Dr Akshay Jain looks into possible reasons why.
  • How Has COVID-19 Affected People With Migraine? Lifestyle changes and stresses as a result of the pandemic, as well as the virus itself, have made an impact on patients with migraine.
  • AF Ablation Latest: Whom to Treat and How Early to Intervene   Drs Thomas Munger and Peter Noseworthy weigh the results of recent data on early intervention in AF in light of CABANA and other trials.
  • Navigating Prior Authorization and Costs for HFrEF Drugs Online tools and decision aids can help clinicians and patients work through the barriers that have slowed the use of new drugs such as sacubitril-valsartan.